Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 218-378-2 | CAS number: 2137-18-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
There is no acute toxicity study conducted with ZK 5686; read across approach with results of studies with gestonorone coproate (ZK 5623):
Oral (Mouse, non-GLP): LD50 > 4000 mg/kg
[Schering AG, 1968-07-31]
Oral (Rat, non-GLP): LD50 > 4000 mg/kg
[Schering AG, 1971-07-08]
Subcutaneous (Mouse, non-GLP): LD50 > 4000 mg/kg
[Schering AG, 1968-07-31]
Subcutaneous (Guinea pig-White Pirbright, non-GLP): LD50 > 8000 mg/kg
[Schering AG, 1965-04-13]
Intraperitoneal (Mouse, non-GLP): LD50 > 4000 mg/kg
[Schering AG, 1968-07-31]
Intraperitoneal (Mouse-NMRI, non-GLP): LD50 = 6000 mg/kg
[Schering AG, 1965-04-13]
Intraperitoneal (Rat-Wistar, non-GLP): LD 50 = 7000 mg/kg
[Schering AG, 1965-04-13]
Intramuscular (Dog-Beagle, female, non-GLP): LD50 > 150 mg/kg (2000 g/dog)
[Schering AG, 1966-11-29]
Key value for chemical safety assessment
Additional information
There is no acute toxicity study conducted with ZK 5686 (gestonorone). Results of studies conducted with an ester of gestonorone (gestonorone caproate, ZK 5623) are regarded as representative as most likely ester cleavage occurs in vivo after administration.
The single oral administration of a microcristalline suspension of ZK 5623 to male and female mice at a dose of 4000 mg/kg caused transient clinical signs (apathy) immediately after administration. All animals were without compound-related clinical signs from Day 2 onwards. No compound-related macroscopic pathological signs were observed. The acute oral toxicity of ZK 5623 in mice is above 4000 mg/kg body weight. [Schering AG, 1968-07-31]
The single oral administration of a microcristalline suspension of ZK 5623 to male and female rats at a dose of 4000 mg/kg was tolerated without any compound-related clinical or macroscopic pathological signs. The acute oral toxicity of ZK 5623 in rats is above 4000 mg/kg body weight. [Schering AG, 1971-07-08]
The single subcutaneous administration of a microcristalline suspension of ZK 5623 to male and female mice at a dose of 4000 mg/kg was tolerated without any compound-related clinical or macroscopic pathological signs. The acute subcutaneous toxicity of ZK 5623 in mice is above 4000 mg/kg body weight. [Schering AG, 1968-07-31]
The single subcuatenous administration of a microcristalline suspension of ZK 5623 to male and female guinea pigs at 8000 and 16000 mg/kg revealed transient apathy at the high dose. All animals were without symptoms from Day 2 onwards during the observation period. The acute subcutaneous toxicity of ZK 5623 in guinea pigs is above 8000 mg/kg body weight. [Schering AG, 1965-04-13]
The single intraperitoneal administration of a microcristalline suspension of ZK 5623 to male and female mice at a dose of 4000 mg/kg caused transient clinical signs (apathy) immediately after administration. All animals were without compound-related clinical signs from Day 2 onwards. One female animal (1/10) died on Day 10. No compound-related macroscopic pathological signs were observed. The acute i.p. toxicity of ZK 5623 in male mice is above 4000 mg/kg body weight. [Schering AG, 1968-07-31]
The single intraperitoneal administration of a microcristalline suspension of ZK 5623 to male mice revealed a LD50 of 6000 mg/kg. Animals died on Days 2 to 3 after administration. Clinical signs in moribund animals were apathy and prone position. [Schering AG, 1965-04-13]
The single intraperitoneal administration of a microcristalline suspension of ZK 5623 to male rats revealed a LD50 of 7000 mg/kg. Animals died on Days 2 to 4 after administration. Clinical signs in moribund animals were apathy. [Schering AG, 1965-04-13]
The single intramuscular administration of a microcristalline suspension of ZK 5623 to female Beagle dogs at a maximum dose of appr. 150 mg/kg caused transient local intolerance reactions at the application site up to Day 10 after administration and secondary effects on general condition in one animal at the high dose (increased body temperature, apathy and anorexia). All animals survived the observation period. No necropsy was performed. The acute toxicity of ZK 5623 after intramuscular administration in Beagle dogs is above approximately 150 mg/kg (2000 g/dog) [Schering AG, 1966-11-29]
Justification for classification or non-classification
For oral administration classification according to Directive 67/548/EEC and Regulation 1272/2008/EC is not required since LD50 <2000 mg/kg.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.